Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
acute disseminated encephalomyelitis
adverse drug reaction
anti MAG antibodies
antibodies to myelin basic protein
antimyelin antibodies
asymptomatic
axonal degeneration
axonal transection
Barkhof MR criteria for MS
BCG vaccination
BENEFIT study
brain atrophy
brain volume
brainstem
brainstem, lesion of
cerebrospinal fluid
cerebrospinal fluid, abnormal
cerebrospinal fluid, oligoclonal IgG in
cerebrospinal fluid, protein of
children
controversies in neurology
cop 1
corpus callosum, lesion of
demyelinating disease
diabetes insipidus
diagnostic criteria
disability rating scale, neurological
disability, neurological
efficacy
Epstein-Barr virus
evoked potentials
fourth ventricle, shift of
gadolinium
gammaglobulin therapy, intravenous
hearing loss
hearing loss, sudden, unilateral
heralding manifestation
herpes virus
hydrocephalus
hydrocephalus, exvacuo
immunomodulation
immunosuppressive agents
interferon
interferon beta 1-a
interferon beta 1-b
intravenous
McDonald criteria for MS
misdiagnosis
mitoxantrone
MRI
MRI, abnormal
MRI, contrast enhanced
MRI, demyelinating disease
MRI, false negative
MRI, field strength
MRI, field strength, high
MRI, incidental finding
MRI, lesion burden
MRI, negative
MRI, optic nerve
MRI, serial
MRI, spinal cord
MRI, volumetry
MRS
multiple sclerosis
multiple sclerosis, asymptomatic
multiple sclerosis, children
multiple sclerosis, chronic progressive
multiple sclerosis, clinical patterns
multiple sclerosis, conversion to clinically definite
multiple sclerosis, diagnosis of
multiple sclerosis, diagnostic criteria
multiple sclerosis, differential diagnosis of
multiple sclerosis, disability status scale
multiple sclerosis, etiology of
multiple sclerosis, misdiagnosis
multiple sclerosis, monosymptomatic
multiple sclerosis, MRI conversion
multiple sclerosis, MRI criteria
multiple sclerosis, pathogenesis
multiple sclerosis, preclinical
multiple sclerosis, prognosis
multiple sclerosis, prophylaxsis
multiple sclerosis, radiologically isolated syndrome
multiple sclerosis, relapsing
multiple sclerosis, risk factors for
multiple sclerosis, secondary progressive
multiple sclerosis, treatment of
multiple sclerosis, treatment of, first attack
N-acetyl-L-aspartic acid
neurologic disease, diagnoses of
neurologic signs
neurologic symptoms
neuropathology
neuroprotective agents
optic nerve, lesion of
optic neuritis
optic neuritis, etiology of
optic neuritis, treatment of
optical coherence tomography
periventricular leukomalacia
posterior fossa
posterior fossa, lesion of
practice guidelines
pregnancy, neurologic complications in
prevention of neurologic disorders
prognosis
protein 14-3-3, cerebrospinal fluid
review article
risk factors
safety
sensorineural hearing loss
serologic testing
spinal cord
spinal cord, lesion of
steroid
steroid therapy, CNS treatment and complications with
symmetric brain lesions
symptomatic
tinnitus
treatment of neurologic disorder
ventricular enlargement
viral infection
visual evoked response
white matter disease, periventricular
Showing articles 250 to 300 of 4024 << Previous Next >>

Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014

Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Subacute Sclerosing Panencephalitis
Adams & Victors Principles of Neurology, Chp 33, pg 766, Ropper, A.H.,et al, 2014

Herpes Simplex Virus Encephalitis:Clinical Manifestations,Diagnosis and Outcome in 106 Adult Patients
J Clin Virol 60:112-118, Sili,U.,et al, 2014

Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014

Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013

Anti-Aquaporin-4 Antibody-Seronegative NMO Spectrum Disorder with Balos Concentric Lesions
Intern Med 52:1517-1521, Masuda, H.,et al, 2013

An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
AJNR 34:2075-2082, Desikan, R.S.,et al, 2013

Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013

Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013

Characterising Aggressive Multiple Sclerosis
JNNP doi:10.1136 1-7, Menon, S.,et al, 2013

Clinicopathologic Conference, Blind and Confused, Neuromyelitis Optica Spectrum Disorder
JAMA Neurol 70:932-936, Sharma, V.,et al, 2013

Subacute Sclerosing Panencephalitis
www.MedLink.com, February, Auwaeter,P.G.&Johnson,R.T., 2013

Three Times Weekly Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis
Ann Neurol 73:705-713, Khan, O.,et al, 2013

Interdependence and Contributions of Sun Exposure and Vitamin D to MRI Measures in Multiple Sclerosis
JNNP 84:1075-1081, 1066, Zivadinov, R.,et al, 2013

The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013

Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013

Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013

Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:190-194, Gold, R.,et al, 2013

Functional Impairment in Progressive Supranuclear Palsy
Neurol 80:380-384, Duff, K.,et al, 2013

Varicella-Zoster Virus Acute Myelitis in a Patient with MS Treated with Natalizumab
Neurol 80:1812-1813, Yeung, J.,et al, 2013

Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200,2176, Maringer, R.,et al, 2013

Aquaporin-4 Antibody-Positive Cases Beyond Current Diagnosis Criteria for NMO Spectrum Disorders
Neurol 80:2210-2216, Sato, D.,et al, 2013

Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013

Extensive Vasogenic Edema of Anti-Aquaporin-4 Antibody-Related Brain Lesions
Mult Scler 15:1113-1117, Matsushita, T.,et al, 2013

Brain Abnormalities as an Initial Manifestation of Neuromyelitis Optica Spectrum Disorder
MSJ 17:1107-1112, Kim, W.,et al, 2013

Clinical Spectrum of CNS Aquaporin-4 Autoimmunity
Neurol 78:1179-1185, Kim, S.,et al, 2013

Differential Diagnosis of Neuromyelitis Optica Spectrum Disorders
Brain Neurol 62:953-960, Tanaka, T., 2013

Aquaporin-4 Antibody-Negative Neuromyelitis Optica
Neurol 80:2194-2200, 2176, Marignier, R.,et al, 2013

Cerebral Venous Thrombosis after High Dose Steroid in Multiple Sclerosis: A Case Report
Hippokratia 17:88-90, Gazioglu, S.,et al, 2013

Clinical Features of MS Associated with Leber Hereditary Optic Neuropathy mtDNA Mutations
Neurol 81:2073-2081, Pfeffer, G.,et al, 2013

Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
Ann Neurol 74:679-687, Krueger, D.A.,et al, 2013

Brain Abnormalities in Neuromyelitis Optica Spectrum Disorder
Multiple Sclerosis International ID 735486, Kim, W.,et al, 2012

Brain Atrophy is Related to Lacunar Lesions and Tissue Microstructural Changes in CADASIL
Stroke 38:1786-1790, Jouvent, E.,et al, 2012

Current Concept of Neuromyelitis Optica (NMO) and NMO Spectrum Disorders
JNNP doi:10.1136/JNNP-2012-302310, Jacob, A.,et al, 2012

Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012

Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis verus Healthy Controls
AJNR 33:252258, Habib,C.A.,et al, 2012

Fingolimod-Associated Macular Edema
Neurol 78:672-680, Jain,N. and Bhatti,M.T., 2012

Serologic Diagnosis of NMO
Neurol 78:665-671, Waters,P.J.,et al, 2012

Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012

Recovery after Spinal Cord Infarcts
Neurol 78:114-121, Robertson,C.E.,et al, 2012

Neuromyelitis Optica and Pregnancy
Neurol 78:875-879, Bourre,B.,et al, 2012

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
NEJM 366:1000-1009, Comi,G.,et al, 2012

Diffusion-weighted imaging characteristics of biopsy-proven demyelinating brain lesions
Neurol 78:1655-1662, Abou Zeid, N.,et al, 2012

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012

"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012

Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012

Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012

Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012

Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012



Showing articles 250 to 300 of 4024 << Previous Next >>